Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phenotype/Genotype Discrepancy of DPD Deficiency Screening in a Patient With Severe Capecitabine Toxicity: A Case Report.

JCO precision oncology - 1 Mar 2023

Poumeaud François, Dalenc Florence, Mathevet Quentin, Brice Aurélie, Eche-Gass Audrey, De Maio D'Esposito Eleonora, Brac-de-la-Perriere Clémence, Thomas Fabienne

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Capecitabine
Share to Fluorouracil
Share to Genotype
Share to Phenotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36926988
DOI: 10.1200/PO.22.00508

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phenotype/Genotype Discrepancy of DPD Deficiency Screening in a Patient With Severe Capecitabine Toxicity: A Case Report.PMID 36926988Read ↗

Preemptive screening of DPYD as part of clinical practice: high prevalence of a novel exon 4 deletion in the Finnish population.Semantic proximity Read ↗

DPYD genotype should be extended to rare variants: report on two cases of phenotype / genotype discrepancy.Semantic proximity Read ↗

DPYD genotyping and predicting fluoropyrimidine toxicity: where do we stand?Semantic proximity Read ↗

Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines.Semantic proximity Read ↗

Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency.Semantic proximity Read ↗

Response to the FDA Decision Regarding DPYD Testing Prior to Fluoropyrimidine Chemotherapy.Semantic proximity Read ↗

Ethnic Diversity of DPD Activity and the DPYD Gene: Review of the LiteratureSemantic proximity Read ↗

All You Need to Know About DPYD Genetic Testing for Patients Treated With Fluorouracil and Capecitabine: A Practitioner-Friendly GuideSemantic proximity Read ↗

The clinical relevance of multiple DPYD polymorphisms on patients candidate for fluoropyrimidine based-chemotherapy. An Italian case-control studySemantic proximity Read ↗

Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper.Semantic proximity Read ↗

Should DPD analysis be required prior to prescribing fluoropyrimidines?Semantic proximity Read ↗

Uncommon dihydropyrimidine dehydrogenase mutations and toxicity by fluoropyrimidines: a lethal case with a new variant.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.